Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock
PR Newswire - Thu Sep 04, 3:01PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date"
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury
Business Wire - Wed Aug 27, 8:01AM CDT
--FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million in Trial Funding
Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
PR Newswire - Wed Aug 27, 5:00AM CDT
Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the successful completion of the Phase 1 clinical study of the product, and is designed to assess safety and activity of escalating doses of AST-OPC1 in patients with complete cervical spinal cord injuries, the first targeted indication for AST-OPC1 and the first of future product registration clinical trials.
Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
PR Newswire - Mon Aug 25, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business strategy and product development pipeline.
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
PR Newswire - Thu Aug 21, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy"